{"id":11446,"date":"2020-05-12T08:30:01","date_gmt":"2020-05-12T12:30:01","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=11446"},"modified":"2026-01-28T13:49:38","modified_gmt":"2026-01-28T18:49:38","slug":"ozempic-vs-trulicity","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/ozempic-vs-trulicity\/","title":{"rendered":"Ozempic vs. Trulicity: Differences, similarities, and which is better for you"},"content":{"rendered":"

Ozempic<\/span><\/a> and <\/span>Trulicity<\/span><\/a> are two commonly prescribed injectable medications used to manage <\/span>Type 2 diabetes<\/span><\/a>. While they are in the same class of drugs and share many similarities, they have key differences in active ingredients, dosage, and cost.<\/span><\/p>\n

Neither is an <\/span>insulin<\/span><\/a>, but they are potent prescription medications that can improve blood sugar control, aid in weight loss, and reduce the risk of serious cardiovascular events. If your healthcare provider has suggested a GLP-1 receptor agonist, comparing Ozempic and Trulicity can help you understand which option might be best for your treatment plan.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Main differences between Ozempic and Trulicity<\/span><\/h2>\n<\/th>\n<\/tr>\n<\/thead>\n

<\/td>\nOzempic<\/b><\/td>\nTrulicity<\/b><\/td>\n<\/tr>\n
Drug class<\/span><\/td>\nGlucagon-like peptide 1 (GLP-1) receptor agonist<\/span><\/td>\nGlucagon-like peptide 1 (GLP-1) receptor agonist<\/span><\/td>\n<\/tr>\n
Brand\/generic status<\/span><\/td>\nBrand (made by Novo Nordisk)\u00a0<\/span><\/td>\nBrand (made by Eli Lilly and Company)\u00a0<\/span><\/td>\n<\/tr>\n
What is the generic name?<\/span><\/td>\nSemaglutide is the active ingredient, but there is no generic version available at this time<\/span><\/td>\nDulaglutide is the active ingredient, but there is no generic version available at this time<\/span><\/td>\n<\/tr>\n
What form(s) does the drug come in?<\/span><\/td>\nPen injection for subcutaneous injection\u00a0<\/span><\/td>\nPen injection for subcutaneous injection<\/span><\/td>\n<\/tr>\n
What is the standard dosage?<\/span><\/td>\nStarting dose<\/span><\/a>: 0.25 mg once weekly. The healthcare provider will gradually increase the dose to a maximum of 2 mg weekly.<\/span><\/td>\nStarting dose<\/span><\/a>: <\/span>0.75 mg once weekly. The healthcare provider may increase the dose, if needed, to a maximum of 4.5 mg weekly.<\/span><\/td>\n<\/tr>\n
How long is the typical treatment?<\/span><\/td>\nVaries; long-term<\/span><\/td>\nVaries; long-term<\/span><\/td>\n<\/tr>\n
Who typically uses the medication?<\/span><\/td>\nAdults 18 years and older<\/span><\/td>\nAdults and children 10 years and older<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

What are the main differences between Ozempic and Trulicity?<\/span><\/h2>\n

Ozempic<\/span><\/a> and <\/span>Trulicity<\/span><\/a> belong to a drug class called <\/span>GLP-1 agonists<\/span><\/a>, also known as glucagon-like peptide agonists. Both drugs are available in brand-name only. The active ingredient in Ozempic is semaglutide, and the active ingredient in Trulicity is dulaglutide. However, neither drug is currently available in generic form. Both drugs are available in a pen injection form. With each weekly dose, the medication is injected subcutaneously into the abdomen, thigh, or upper arm. We\u2019ll discuss each drug in more detail below.\u00a0<\/span><\/p>\n

Conditions treated by Ozempic and Trulicity<\/span><\/h2>\n

Ozempic and Trulicity both have several FDA-approved uses, as outlined in the table below. These drugs are also sometimes prescribed <\/span>off-label<\/span><\/a> (for a non-FDA-approved use) for weight loss.\u00a0<\/span><\/p>\n\n\n\n\n
Ozempic FDA-approved uses<\/b><\/td>\nTrulicity FDA-approved uses<\/b><\/td>\n<\/tr>\n
\n
    \n
  • To improve blood sugar control in adults with Type 2 diabetes (along with diet and exercise)<\/span><\/li>\n
  • To reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with Type 2 diabetes and heart disease<\/span><\/li>\n
  • To reduce the risk of further kidney decline and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease<\/span><\/li>\n<\/ul>\n<\/td>\n
\n